Recordati acquires EUSA Pharma and its 4 rare disease drugs, but analysts question strategy behind the deal

Max Gelman

Senior Editor

An Italian pharma company engineered a nearly $850 million buyout last week looking to expand its rare disease portfolio and further soak up parts of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Recordati acquires EUSA Pharma and its 4 rare disease drugs, but analysts question strategy behind the deal

Max Gelman

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

Post-Hoc: Pharma CEOs' alternative reality with Trump

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

FDA approves first drug to treat ultra-rare lipid storage disease

How AI can address ongoing challenges in the life sciences industry

Recor­dati ac­quires EU­SA Phar­ma and its 4 rare dis­ease drugs, but an­a­lysts ques­tion strat­e­gy be­hind the deal

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Recordati acquires EUSA Pharma and its 4 rare disease drugs, but analysts question strategy behind the deal